**Metformin** and **glucagon-like peptide-1 receptor agonists (GLP-1RA)** significantly reduce the risk of asthma attacks in patients with both asthma and Type 2 diabetes.

In a large cohort study using data from the UK Clinical Practice Research Datalink, metformin was associated with a **30%** reduction in asthma attacks. Adding GLP-1RA further reduced the risk by an additional **40%**. 

These findings were consistent regardless of factors like glycemic control, body mass index (BMI), or asthma severity. 

The study utilized two analytical approaches: a self-controlled case series and a cohort study, with both showing similar results. The study found no significant bias in the analyses, and the protective effect of these medications was observed across different asthma phenotypes. 

*These findings suggest that metformin and GLP-1RA may benefit asthma control in patients with Type 2 diabetes through mechanisms beyond just improving glycemic control or reducing weight.*
                                                                                                                                                                                                         Source: JAMA Internal Medicine [Read full story](https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2826086)